Form 4: Fulgent Genetics CSO Sells Shares for Tax Obligations

Fulgent Genetics' Chief Scientific Officer, Hanlin Gao, sold 943 shares of common stock on November 28, 2025, to cover tax withholding obligations related to RSU vesting.

Summary

• Hanlin Gao, Chief Scientific Officer of Fulgent Genetics, Inc. (FLGT), reported a transaction involving the sale of common stock.
• On November 28, 2025, 943 shares of common stock were sold.
• The shares were sold at a weighted-average price of $29.5695 per share, with individual transactions ranging from $29.45 to $29.67.
• The purpose of the sale was to satisfy tax withholding obligations arising from the vesting of restricted stock units (RSUs).
• These RSUs were originally granted to Hanlin Gao on February 26, 2024, and reported on a Form 4 filed on February 28, 2024.
• Following this transaction, Hanlin Gao beneficially owns 953,965 shares of Fulgent Genetics common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale to cover tax obligations related to RSU vesting, which is a neutral event and does not reflect a change in the insider's sentiment towards the company's prospects.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction for tax purposes and does not provide specific insights into broader industry trends or competitive positioning for Fulgent Genetics.

Stakeholder Impact

• Shareholders: Minimal impact as this is a small, routine transaction for tax purposes and does not indicate a change in the company's fundamentals or management's long-term view.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of a small number of shares by an executive to cover tax obligations upon RSU vesting. Such transactions are common and do not typically signal a change in the company's fundamental outlook or the executive's confidence. Therefore, it provides no new information that would warrant a change in an existing investment thesis, leading to a 'hold' recommendation.

Keywords

Fulgent Genetics, FLGT, Insider Transaction, Form 4, Stock Sale, RSU Vesting, Tax Withholding, Chief Scientific Officer